Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Budesonide Inhalation Formulations
NCT02593500Phase 1Completed
- Sponsor
- Laboratorio Reig Jofre, S.A.
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of budesonide in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Laboratorio Reig Jofre, S.A. Primary endpoints: Maximum Observed Plasma Concentration at 24 hours and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours. Started Apr 2014; status: completed.
02
Drugs
budesonide
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02593500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593500.